Climbazole is a new potent inducer of rat hepatic cytochrome P450.

  • KOBAYASHI Yasuna
    Departments of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University
  • SUZUKI Michiya
    Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University
  • OHSHIRO Naomi
    Departments of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University
  • SUNAGAWA Takashi
    Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University
  • SASAKI Tadanori
    Departments of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University
  • TOKUYAMA Shogo
    Departments of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University
  • YAMAMOTO Toshinori
    Departments of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University
  • YOSHIDA Takemi
    Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University

この論文をさがす

抄録

We examined the effect of climbazole on the induction of rat hepatic microsomal cytochrome P450 (P450), and compared the induction potency with other N-substituted azole drugs such as clorimazole. We found that climbazole is found to be a potent inducer of rat hepatic microsomal P450 as clorimazole. Induced level of P450 by climbazole was almost similar in extent to clorimazole when compared with other imidazole drugs in a dose- and time-dependent manner. Parallel to the increase in P450, climbazole increased aminopyrine and erythromycin N-demethylase, ethoxycoumarin O-deethylase, and androstenedione 16β- and 15α/6β hydroxylase activities; however, clorimazole did not induce aminopyrine N-demethylase activity irrespective of its marked increase in P450 content. Immunoblot analyses revealed that climbazole induced CYP2B1, 3A2 and 4A1. The present findings indicate that climbazole is a new potent inducer of hepatic microsomal P450 and drug-metabolizing enzymes like clorimazole, but it may have some differential mechanism(s) for these enzymes’ induction in rat liver.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (64)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ